-
Featured Authors
Jim’s Corner
Archive
- April 2013 (1)
- February 2013 (4)
- January 2013 (2)
- December 2012 (1)
- November 2012 (2)
- October 2012 (2)
- August 2012 (1)
- July 2012 (2)
- June 2012 (2)
- May 2012 (1)
- April 2012 (1)
- March 2012 (1)
- December 2011 (1)
- August 2011 (2)
- July 2011 (1)
- June 2011 (5)
- May 2011 (1)
- March 2011 (1)
- February 2011 (1)
- January 2011 (2)
- December 2010 (1)
- November 2010 (2)
- October 2010 (1)
- September 2010 (1)
- August 2010 (1)
- July 2010 (2)
- May 2010 (1)
- April 2010 (1)
- March 2010 (2)
- February 2010 (6)
- January 2010 (1)
- November 2009 (2)
- October 2009 (2)
- September 2009 (1)
- August 2009 (2)
- July 2009 (3)
- June 2009 (2)
- May 2009 (6)
- March 2009 (1)
Category Archives: Jim’s Corner
Looking for Long-Term Economic Signs at BIO Partnering Meetings
In its 30-year history, biotechnology has made dramatic advances possible in health care, agriculture, energy production and industrial bioprocessing. These accomplishments are the result of painstaking work by many smart people devoted to transforming bench-scale life-science research into commercial products. In economic times both strong and weak this industry thrives. The industry and the promise of its science were tested during the recent and continuing recession. Many biotech companies were forced to downsize or even Read More >
Millions Around World to Observe Rare Disease Day
On Sunday, Feb. 28, millions of people around the world will observe “World Rare Disease Day”. This is an annual event sponsored in the U.S. by the National Organization for Rare Disorders (NORD) and in Europe by the European Rare Disease Organisation (EURORDIS). Plans for the day—and the days leading up to it—include awareness events sponsored by patient organizations, a rally organized by pre-medical students at the University of Connecticut, a scientific symposium at the Read More >
Biotech Depends on Policies that Promote Innovation
The biotechnology industry’s endeavor to transform science into therapy for a previously untreatable disease is the subject of a new movie, “Extraordinary Measures.” The movie is the story of John Crowley, founder of Novazyme, and his struggle to find funding to develop a therapy for Pompe disease. The story, though, may not seem so out of the ordinary to those in the biotechnology industry who conduct vital research and development on products that will help Read More >
Welcome to BIOtech Now
BIOtech Now is the first in a number of new products from BIO intended to enhance our communications with the biotech community — not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its web site, serves as our flagship in that effort. BIOtech Now will: Offer original content that emphasizes the business needs of the industry. Highlight BIO’s advocacy efforts. Provide a portal to all BIO activities and Read More >
Food and Energy Security: Raising AgriBio’s Profile
The world’s population is projected to reach 9.1 billion by the middle of this century. Feeding that number of people — in addition to producing animal feed, fiber and biofuels — will require a 70 percent increase in overall agricultural production, primarily in the developing world, according to the United Nations Food and Agriculture Organization (UN FAO). That is why the priorities for BIO’s Food and Agriculture Section in the coming year start with increasing Read More >





